$ICUI
ICU Medical Inc

2015 Q2 Form 10-Q Financial Statement

#000088398415000032 Filed on August 10, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q2
Revenue $83.78M $78.68M
YoY Change 6.49% 0.02%
Cost Of Revenue $40.02M $41.14M
YoY Change -2.71% 1.26%
Gross Profit $43.76M $37.54M
YoY Change 16.57% -1.3%
Gross Profit Margin 52.23% 47.72%
Selling, General & Admin $20.32M $24.28M
YoY Change -16.31% 4.73%
% of Gross Profit 46.43% 64.67%
Research & Development $3.122M $4.566M
YoY Change -31.63% 16.9%
% of Gross Profit 7.13% 12.16%
Depreciation & Amortization $4.400M $4.900M
YoY Change -10.2% 0.0%
% of Gross Profit 10.05% 13.05%
Operating Expenses $23.44M $28.84M
YoY Change -18.74% 6.48%
Operating Profit $20.32M $8.698M
YoY Change 133.63% -20.57%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $240.0K $207.0K
YoY Change 15.94% -2.36%
Pretax Income $20.56M $8.905M
YoY Change 130.89% -20.22%
Income Tax $6.991M $3.027M
% Of Pretax Income 34.0% 33.99%
Net Earnings $13.57M $5.878M
YoY Change 130.86% -20.21%
Net Earnings / Revenue 16.2% 7.47%
Basic Earnings Per Share $0.86 $0.39
Diluted Earnings Per Share $0.83 $0.38
COMMON SHARES
Basic Shares Outstanding 15.78M shares 15.24M shares
Diluted Shares Outstanding 16.35M shares 15.36M shares

Balance Sheet

Concept 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $367.3M $315.8M
YoY Change 16.31% 29.43%
Cash & Equivalents $331.1M $252.2M
Short-Term Investments $36.20M $79.90M
Other Short-Term Assets $13.80M $11.30M
YoY Change 22.12% 2.73%
Inventory $38.23M $37.82M
Prepaid Expenses
Receivables $43.43M $41.02M
Other Receivables $8.300M $6.700M
Total Short-Term Assets $471.1M $412.6M
YoY Change 14.15% 19.2%
LONG-TERM ASSETS
Property, Plant & Equipment $81.38M $91.90M
YoY Change -11.45% 3.27%
Goodwill $1.478M $1.478M
YoY Change 0.0% 0.0%
Intangibles $6.415M $7.668M
YoY Change -16.34% -17.3%
Long-Term Investments
YoY Change
Other Assets $9.900M $5.800M
YoY Change 70.69% 3.57%
Total Long-Term Assets $99.19M $106.9M
YoY Change -7.19% 1.42%
TOTAL ASSETS
Total Short-Term Assets $471.1M $412.6M
Total Long-Term Assets $99.19M $106.9M
Total Assets $570.2M $519.5M
YoY Change 9.76% 15.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.59M $11.33M
YoY Change 11.11% -3.44%
Accrued Expenses $16.09M $15.80M
YoY Change 1.85% -3.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.68M $27.13M
YoY Change 5.72% -3.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.200M $2.700M
YoY Change -55.56% -18.18%
Total Long-Term Liabilities $1.200M $2.700M
YoY Change -55.56% -18.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.68M $27.13M
Total Long-Term Liabilities $1.200M $2.700M
Total Liabilities $32.20M $34.10M
YoY Change -5.57% -7.84%
SHAREHOLDERS EQUITY
Retained Earnings $432.2M $395.1M
YoY Change 9.38% 10.3%
Common Stock $123.7M $90.15M
YoY Change 37.18% 29.65%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.188M
YoY Change -88.73%
Treasury Stock Shares 19.00K shares
Shareholders Equity $538.1M $485.5M
YoY Change
Total Liabilities & Shareholders Equity $570.2M $519.5M
YoY Change 9.76% 15.05%

Cashflow Statement

Concept 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income $13.57M $5.878M
YoY Change 130.86% -20.21%
Depreciation, Depletion And Amortization $4.400M $4.900M
YoY Change -10.2% 0.0%
Cash From Operating Activities $15.90M $16.60M
YoY Change -4.22% 9.21%
INVESTING ACTIVITIES
Capital Expenditures -$2.800M -$7.100M
YoY Change -60.56% 14.52%
Acquisitions
YoY Change
Other Investing Activities $9.900M -$4.200M
YoY Change -335.71% -182.35%
Cash From Investing Activities $7.100M -$11.30M
YoY Change -162.83% 927.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.000M 3.700M
YoY Change -154.05% 184.62%
NET CHANGE
Cash From Operating Activities 15.90M 16.60M
Cash From Investing Activities 7.100M -11.30M
Cash From Financing Activities -2.000M 3.700M
Net Change In Cash 21.00M 9.000M
YoY Change 133.33% -41.56%
FREE CASH FLOW
Cash From Operating Activities $15.90M $16.60M
Capital Expenditures -$2.800M -$7.100M
Free Cash Flow $18.70M $23.70M
YoY Change -21.1% 10.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9929000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
3425000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
33000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000883984
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15831046 shares
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
ICU MEDICAL INC/DE
CY2015Q2 icui Debt Securities Maturity Date Range High
DebtSecuritiesMaturityDateRangeHigh
2037
CY2015Q2 icui Debt Securities Maturity Date Range Low
DebtSecuritiesMaturityDateRangeLow
2015
icui Increase Decreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes
IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes
-95000 USD
icui Increase Decreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes
IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes
-5456000 USD
icui Legal Settlement Charge For Legal Fees
LegalSettlementChargeForLegalFees
700000 USD
icui Legalsettlementcharge
Legalsettlementcharge
6500000 USD
icui Provision For Warranty And Returns
ProvisionForWarrantyAndReturns
-597000 USD
icui Provision For Warranty And Returns
ProvisionForWarrantyAndReturns
38000 USD
CY2015Q2 icui Treasury Stock Purchase Plan
TreasuryStockPurchasePlan
40000000 USD
CY2015Q2 icui Treasury Stock Purchase Plan Remaining Available
TreasuryStockPurchasePlanRemainingAvailable
22500000 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11378000 USD
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
12587000 USD
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
39051000 USD
CY2015Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
43428000 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17350000 USD
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16090000 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
138623000 USD
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
145655000 USD
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9554000 USD
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17777000 USD
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
107336000 USD
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
122091000 USD
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1127000 USD
CY2015Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1114000 USD
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
266000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
235000 shares
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16000 shares
CY2014Q4 us-gaap Assets
Assets
541102000 USD
CY2015Q2 us-gaap Assets
Assets
570237000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
437212000 USD
CY2015Q2 us-gaap Assets Current
AssetsCurrent
471052000 USD
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
70952000 USD
CY2015Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
36223000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
140000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
232000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
226022000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
235951000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8828000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275812000 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
331092000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
55280000 USD
CY2014Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
346764000 USD
CY2015Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
367315000 USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15595000 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15794000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15595000 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15794000 shares
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
1559000 USD
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
1579000 USD
CY2014Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
5151000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
11732000 USD
CY2015Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
15438000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
15033000 USD
CY2014Q4 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
0 USD
CY2015Q2 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
0 USD
CY2014Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
41135000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
78338000 USD
CY2015Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
40020000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
78990000 USD
CY2014Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
4683000 USD
CY2015Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
6885000 USD
CY2014Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
9258000 USD
CY2015Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
9916000 USD
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1376000 USD
CY2015Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2278000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9666000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9026000 USD
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.83
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.48
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.81
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.43
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-568000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-6350000 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.34
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.27
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
1985000 USD
CY2014Q4 us-gaap Goodwill
Goodwill
1478000 USD
CY2015Q2 us-gaap Goodwill
Goodwill
1478000 USD
CY2014Q2 us-gaap Gross Profit
GrossProfit
37542000 USD
us-gaap Gross Profit
GrossProfit
73569000 USD
CY2015Q2 us-gaap Gross Profit
GrossProfit
43761000 USD
us-gaap Gross Profit
GrossProfit
86275000 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
8905000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
18992000 USD
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
20561000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
32060000 USD
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3027000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6457000 USD
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6991000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8804000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-134000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1894000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4786000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5529000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
498000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1027000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3456000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2267000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-548000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1375000 USD
CY2014Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
120000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
269000 shares
CY2015Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
571000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
564000 shares
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7063000 USD
CY2015Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6415000 USD
CY2014Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10381000 USD
CY2015Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11837000 USD
CY2014Q4 us-gaap Inventory Net
InventoryNet
36933000 USD
CY2015Q2 us-gaap Inventory Net
InventoryNet
38231000 USD
CY2014Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
23006000 USD
CY2015Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
21885000 USD
CY2014Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
3546000 USD
CY2015Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
4509000 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
1060000 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
1223000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
541102000 USD
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
570237000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28728000 USD
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
28677000 USD
CY2014Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
2746000 USD
CY2015Q2 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1222000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5797000 USD
CY2014Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 USD
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 USD
CY2015Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 USD
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
7059000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4550000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23328000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27052000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
29275000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
25750000 USD
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
207000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
417000 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
240000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
766000 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
28844000 USD
us-gaap Operating Expenses
OperatingExpenses
54994000 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
23440000 USD
us-gaap Operating Expenses
OperatingExpenses
54981000 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
8698000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
18575000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
20321000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
31294000 USD
CY2014Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-727000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-803000 USD
CY2015Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1868000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8223000 USD
CY2014Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-206000 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-227000 USD
CY2015Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
508000 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-2212000 USD
CY2014Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
122000 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
239000 USD
CY2015Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
119000 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
280000 USD
CY2015Q2 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
7500000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1400000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
377000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
440000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
60090000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
17092000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12729000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5005000 USD
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.00
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.00
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5818000 USD
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6930000 USD
CY2014Q4 us-gaap Prepaid Taxes
PrepaidTaxes
3963000 USD
CY2015Q2 us-gaap Prepaid Taxes
PrepaidTaxes
8263000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
49863000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
49555000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
5000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
34000 USD
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7016000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1384000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1041000 USD
CY2014Q2 us-gaap Profit Loss
ProfitLoss
5878000 USD
us-gaap Profit Loss
ProfitLoss
12535000 USD
CY2015Q2 us-gaap Profit Loss
ProfitLoss
13570000 USD
us-gaap Profit Loss
ProfitLoss
23256000 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
224714000 USD
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
227031000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
86091000 USD
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
81376000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
53000 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4566000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8197000 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3122000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7430000 USD
CY2015Q2 us-gaap Restructuring Reserve
RestructuringReserve
100000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
408911000 USD
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
432167000 USD
CY2014Q2 us-gaap Revenues
Revenues
78677000 USD
us-gaap Revenues
Revenues
151907000 USD
CY2015Q2 us-gaap Revenues
Revenues
83781000 USD
us-gaap Revenues
Revenues
165265000 USD
CY2014Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
78555000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
151668000 USD
CY2015Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
83662000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
164985000 USD
CY2014Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24278000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46797000 USD
CY2015Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20318000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
40492000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4459000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5947000 USD
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
16401 shares
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
508252000 USD
CY2015Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
538060000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-5835000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-1435000 USD
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15362000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15439000 shares
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16352000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16302000 shares
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15242000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15170000 shares
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15781000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15738000 shares
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU No. 2014-09.&#160; On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. This guidance will become effective for us at the beginning of the first quarter of 2016. We do not anticipate a material impact on our consolidated financial statements from adoption of this ASU.</font></div></div>

Files In Submission

Name View Source Status
0000883984-15-000032-index-headers.html Edgar Link pending
0000883984-15-000032-index.html Edgar Link pending
0000883984-15-000032.txt Edgar Link pending
0000883984-15-000032-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
icui-20150630.xml Edgar Link completed
icui-20150630.xsd Edgar Link pending
icui-20150630_cal.xml Edgar Link unprocessable
icui-20150630_def.xml Edgar Link unprocessable
icui-20150630_lab.xml Edgar Link unprocessable
icui-20150630_pre.xml Edgar Link unprocessable
icui-ex311_20150630x10q.htm Edgar Link pending
icui-ex312_x20150630x10q.htm Edgar Link pending
icui-ex321_x20150630x10q.htm Edgar Link pending
icui0630201510-q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending